Ecosystem
The ecosystem
BIOASTER is an actor in or member of various networks that aim to facilitate the application of technological innovation in the health sector.
BIOASTER is at the heart of the health ecosystem in France. This positioning allows the Institute to provide its partners with knowledge of the networks that exist in the sector, both to identify and engage the most appropriate players in a project and to promote new synergies and complementarity that benefit all the parties concerned.
Thematic Networks
Hub VPH
BIOASTER is one of the founding partners of the HUB VPH (Veterinary Public Health). The HUB VPH (Veterinary Public Health) is an unprecedented public-private initiative that involves nine major players in the health ecosystem in the Auvergne-Rhône-Alpes region.
This first Veterinary Public Health hub was created on the basis of a common desire: to become a world-class reference center for Veterinary Public Health, and was driven by the strong collaborative tradition in the Auvergne-Rhône-Alpes region and recognition of the importance of addressing international Veterinary Public Health issues.
This first Veterinary Public Health hub was created on the basis of a common desire: to become a world-class reference center for Veterinary Public Health, and was driven by the strong collaborative tradition in the Auvergne-Rhône-Alpes region and recognition of the importance of addressing international Veterinary Public Health issues.
Bioproduction
TWB
BIOASTER is a member of the Toulouse White Biotechnology (TWB) consortium. TWB provides concrete assistance for companies and biotechnology entrepreneurs in the development of products and processes using bio-sourced raw materials, from the laboratory to the pre-industrial pilot stage. As a member of the Strategic Orientation Committee, BIOASTER contributes to the definition of TWB’s roadmap and to the annual selection of self-financed public research projects, using its knowledge and vision regarding biotechnology and technological tools.
France Biolead
France BioLead, the French biomanufacturing sector, brings together all the players of French biomanufacturing, including manufacturers (pharmaceutical and biotechnology companies, CDMOs, CROs, equipment manufacturers, suppliers of technological solutions and consumables), academic research, training providers, the French government and competitive clusters, associations and professional unions.
Its ambition is to structure and manage a unique French biomanufacturing industry with the support of the French government, to make France a leader in biomanufacturing in Europe.
AMR
S.O.L.V.E. AMR
Solutions for Overcoming and Leveraging Versatile Efforts Against Microbial Resistance
Pioneering initiative to Fast-Track Antimicrobials from R&D to commercialization This hub is dedicated to support innovative AMR solutions for Biopharma Companies. BIOASTER, Cynbiose www.cynbiose.com, ICTA www.icta-group.com, and PharmaLex www.pharmalex.com have launched a strategic collaboration that aims to help combat antimicrobial resistance (AMR). As
part of the initiative, the organizations will leverage their collective expertise and capabilities to offer innovative and integrated support from discovery, pre-clinical and clinical drug development processes up to registration and commercialization, helping to accelerate the development of antimicrobials.
To know more: derry.mercer@bioaster.org
Pioneering initiative to Fast-Track Antimicrobials from R&D to commercialization This hub is dedicated to support innovative AMR solutions for Biopharma Companies. BIOASTER, Cynbiose www.cynbiose.com, ICTA www.icta-group.com, and PharmaLex www.pharmalex.com have launched a strategic collaboration that aims to help combat antimicrobial resistance (AMR). As
part of the initiative, the organizations will leverage their collective expertise and capabilities to offer innovative and integrated support from discovery, pre-clinical and clinical drug development processes up to registration and commercialization, helping to accelerate the development of antimicrobials.
To know more: derry.mercer@bioaster.org
Beam alliance
As an associate member of the Biotech companies in Europe combating AntiMicrobial Resistance (BEAM) alliance, BIOASTER contributes to the federation of European initiatives to tackle antimicrobial resistance. BIOASTER’s relationships with some of the SME participants in the BEAM alliance manifest as joint research projects, such as DACCAR with Da Volterra and PhagUTI with Pherecydes Pharma.
Antibiodeal
Afin de structurer la recherche française et le développement de nouveaux agents antimicrobiens, le réseau AntibioDEAL a été créé dans le cadre du méta- réseau professionnel PROMISE soutenu par le Plan Prioritaire de Recherche
sur la résistance aux antibiotiques. Les objectifs principaux d’AntibioDEAL sont :
– D’inventorier et connecter les forces nationales impliquées dans la découverte de nouveaux antibiotiques ;
– D’identifier les freins de la recherche et prioriser les verrous à lever ;
– De proposer et diffuser des solutions pour contourner ou lever ces freins.
sur la résistance aux antibiotiques. Les objectifs principaux d’AntibioDEAL sont :
– D’inventorier et connecter les forces nationales impliquées dans la découverte de nouveaux antibiotiques ;
– D’identifier les freins de la recherche et prioriser les verrous à lever ;
– De proposer et diffuser des solutions pour contourner ou lever ces freins.
Incate
INCATE (the INCubator for Antibacterial Therapies in Europe) and BIOASTER, the French Microbiology Technology Research Institute, have announced a new partnership that aims to improve the support to innovators to fight drug- resistant infections.
To read the PR: mettre le lien vers le CP
To know more: derry.mercer@bioaster.org
To read the PR: mettre le lien vers le CP
To know more: derry.mercer@bioaster.org
Microbiota
Cynbiome
Cynbiome® is a preclinical network dedicated to research into the microbiome that aims to capitalize on the richness and complementarity of players specializing in fields such as high-throughput sequencing, biomanufacturing, imaging, microfluidics, specific analyses, biomarkers, and preclinical and clinical activities.
Cynbiome® undertakes preclinical R&D activities, focusing on the microbiome and infectious diseases.
BIOASTER is a player in the development of innovative technologies for healthcare purposes, bringing its expertise, means, and resources to the pursuit of these objectives, and is an enthusiastic participant in the partnership and collaborative approaches to the development of common objectives and projects.
Cynbiome® undertakes preclinical R&D activities, focusing on the microbiome and infectious diseases.
BIOASTER is a player in the development of innovative technologies for healthcare purposes, bringing its expertise, means, and resources to the pursuit of these objectives, and is an enthusiastic participant in the partnership and collaborative approaches to the development of common objectives and projects.
Pharmabiotic Research Institute
The PRI was founded to make Microbial Medicinal Products a therapeutic reality in Europe. The PRI believes that the microbiome represents the future of human medicine. The members have stakes in the regulatory, technical, and collaborative efforts regarding the microbiome and human health space. Dr Vincent Thomas, Head of the Microbiota Program at BIOASTER, is a PRI Board Member.
EMIH
BIOASTER is one of the founders of the EMIH. The goal of the EMIH is to promote medical innovation, based on the microbiota, as one of the public health priorities within the European Union. Its members are committed to developing advances in therapeutic, diagnostics and medical bioproduction based on the microbiota, in the field of human health, through a framework meeting the highest quality standards and also allowing economic balance, in order to maintain therapeutic innovation.
Support & valorization
SATT
More broadly, BIOASTER communicates and collaborates on a case-by-case basis with other SATTs (Technology Transfer Acceleration Companies). BIOASTER performs studies at the request of a SATT or provides observations regarding the maturity of the technologies supported by SATTs.
Pulsalys
BIOASTER and Pulsalys signed a memorandum of understanding in 2017. This cooperation agreement aims to combine the complementary expertise of the two partners. BIOASTER and PULSALYS agreed to:
- undertake discussions in order to identify opportunities for joint projects, and in particular projects in which BIOASTER would validate, and if appropriate, disseminate technologies developed by PULSALYS
- consider access for BIOASTER to the services offered by PULSALYS, in particular with respect to intellectual property management.
- discuss best practices regarding innovation, technology transfer, and the protection of research findings.
Competitiveness – Institutional customers
LyonBiopôle
BIOASTER is a member of the LyonBiopôle competitiveness cluster. The LyonBiopôle represents an innovative and fertile health ecosystem with international connections within the Auvergne-Rhône-Alpes region.
BIOASTER has been part of this global competitiveness cluster since its creation in 2005. It supports projects and companies in the sector and aims to aid the development of technological innovations, products, and services to meet the health challenges of tomorrow.
BIOASTER has been part of this global competitiveness cluster since its creation in 2005. It supports projects and companies in the sector and aims to aid the development of technological innovations, products, and services to meet the health challenges of tomorrow.
Medicen
Crée en 2005, Medicen Paris Région est le pôle de compétitivité santé de la Région Île-de-France. Son réseau unique fédère plus de 510 acteurs de l’innovation en santé parmi lesquels 430 startups et PME de la healthtech, les industriels de la santé, les principaux instituts de recherche nationaux et établissements de soins du territoire.
FIT
BIOASTER, as an IRT, is a member of the FIT association, the “French Institute of Technology”, which was created in 2014. The FIT association brings together 15 institutes that were created as part of the Future Investments Program (PIA) and share the same fundamental principles regarding public-private multi-partner research. Within the FIT association, IRTs and ITEs are strengthening their ties and maximizing their competencies, with the aim of identifying home-grown, sustainable, and resilient technological innovations that accelerate environmental, digital, and societal transitions in our territories.